超越疗法

2023年2月27日

超越疗法提出了40美元的A轮α波全球和集成VC 2月27日,2023 |下午3:36 2分钟阅读超越疗法关闭一系列一轮融资4000万美元与主要来自α波全球和综合投资合作伙伴的支持。成立于2021年,由领先的早期VS AlleyCorp孵化,下一代的精神药物公司已经筹集了近4200万美元的日期和预计使用的新资金启动几个临床试验包括一个第二阶段研究的先导化合物。作为公共利益集团(PBC),超越已承诺成立10%的股份向非营利组织致力于科学研究和病人的访问。超越不关注古典迷幻药,而是精神上的亚甲基化合物;专有名称是tsnd - 201。这下一代复合短效和温和的心理影响,因此需要临床医生的时间更短。可以使用它作为一个现有的几种药物的辅助治疗,使其适合集成到现有的精神范式和医疗基础设施。明显,tsnd - 201拥有以前的人类经验,在治疗创伤后应激障碍患者和真实数据展示强大的反应。“心理健康疾病残疾的主要原因之一,在美国和全球范围内,还可以为很多病人治疗是无效的,可以花费数周时间发挥作用,并且经常有长期的副作用。在超越,我们正在努力改变,开始通过将新一代化合物,methylone,市场潜在的快速,疾病修饰,non-hallucinogenic治疗创伤后应激障碍等神经精神疾病,”联合创始人兼首席执行官布雷克Mandell说道。 Transcend co-founder/chairman and AlleyCorp founder/CEO Kevin Ryan says the current advancements in mental healthcare hold a parallel to those of the Internet in 1996. “Even the most hopeful people underestimate its impact on the world,” Ryan stated, adding that Transcend’s work “has the potential to completely change how people are treated for PTSD and depression" by bringing together “the world's leaders in drug development and psychiatric research” and pushing together this industry forward “into new, highly promising territory." Alpha Wave Global co-founder and CIO Rick Gerson said Transcend’s combination of team and “well-characterized lead compound” have the potential “to make a meaningful impact in the lives of millions." He said he was confident that the new funding will accelerate the firm's work to bring methylone to market sooner while beginning to build out a pipeline of other promising compounds. Join us at our second edition of the Benzinga Psychedelics Capital Conference at the Fontainebleau Miami Beach Hotel in Florida on April 13. This is THE place to get DEALS DONE, raise money, jumpstart M&A and meet investors and key partners.